Feldan Therapeutics and Elasmogen Announce Research Agreement with Amgen to Develop Intracellular Biologics

On May 9, 2017 Elasmogen Ltd, focused on the development of next generation biologics, and Feldan Therapeutics, focused on intracellular delivery of proteins, reported a research collaboration with Amgen, to develop and deliver novel intracellular biologics (Press release, Elasmogen, MAY 9, 2017, View Source [SID1234637762]). The collaboration combines the unique capabilities of Feldan’s Shuttle platform and Elasmogen’s soloMER technology to develop the delivery system and binding domains to two undisclosed intracellular targets for Amgen.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Feldan Shuttle technology is a novel peptide-based delivery method that enables the highly efficient introduction of foreign proteins into cells. Elasmogen’s soloMER’s are the smallest naturally occurring binding domains. Their small size and robust nature, particularly the resistance to changes in pH and ability to bind in intracellular conditions makes them the perfect complement to Feldan’s technology.

"Currently all approved biologic antibody therapeutics act on extracellular targets but intracellular delivery enables access to a much greater number of targets," said François-Thomas Michaud, CEO, Feldan Therapeutics. "Intracellular delivery and binding of biologics can bridge the gap between small molecules and biologics."

"This is an exciting opportunity to demonstrate the performance and capabilities of the combined Shuttle-soloMER technology. The expertise provided by Amgen will significantly accelerate the development of this potential new class of therapeutics," said Caroline Barelle, CEO, Elasmogen.

In 2016, Feldan and Elasmogen established an exclusive partnership for the development of intracellular biologics. Working together, their research teams have demonstrated both intracellular and intranuclear delivery of soloMER binding domains.